Virpax Pharmaceuticals Stock Working Capital
| VRPXDelisted Stock | USD 0.25 0.04 19.05% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Virpax Pharmaceuticals' long-term financial health and intrinsic value.
Virpax |
Virpax Pharmaceuticals Company Working Capital Analysis
Virpax Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Virpax Pharmaceuticals Working Capital | (913.76 K) |
Most of Virpax Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Virpax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAs per the company's disclosures, Virpax Pharmaceuticals has a Working Capital of (913,760). This is 100.21% lower than that of the Biotechnology sector and 100.17% lower than that of the Health Care industry. The working capital for all United States stocks is 100.06% higher than that of the company.
Virpax Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Virpax Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Virpax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Virpax Pharmaceuticals by comparing valuation metrics of similar companies.Virpax Pharmaceuticals is currently under evaluation in working capital category among its peers.
Virpax Fundamentals
| Return On Equity | -23.65 | ||||
| Return On Asset | -1.35 | ||||
| Current Valuation | (1.21 M) | ||||
| Shares Outstanding | 1.24 M | ||||
| Shares Owned By Insiders | 0.96 % | ||||
| Shares Owned By Institutions | 0.41 % | ||||
| Number Of Shares Shorted | 577.07 K | ||||
| Price To Book | 0.48 X | ||||
| EBITDA | (12.08 B) | ||||
| Net Income | (12.07 B) | ||||
| Cash And Equivalents | 26.06 M | ||||
| Cash Per Share | 2.22 X | ||||
| Total Debt | 2.47 B | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 11.84 X | ||||
| Book Value Per Share | (1.53) X | ||||
| Cash Flow From Operations | (16.71 B) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (71.00) X | ||||
| Target Price | 3.0 | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 831.85 K | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (71.61 B) | ||||
| Working Capital | (913.76 K) | ||||
| Net Asset | 1.56 B |
About Virpax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Virpax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virpax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virpax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Virpax Pink Sheet
If you are still planning to invest in Virpax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virpax Pharmaceuticals' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |